Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome Ovarian Cancer Stem Cells
Abstract
:1. Introduction
2. Results
2.1. Synthesis and Characterization of SSBPEI–DOX@siRNAs/iRGD–PEG–HA Nanoparticles
2.2. Extraordinary Stability and Reduction Sensitivity of SSBPEI–DOX@siRNAs/iRGD–PEG–HA Nanoparticles
2.3. Validation of Biological Characteristics of Stem Cell Microspheres
2.4. Dual Targeting Ability of the Nanoparticles In Vitro/Vivo
2.5. The Efficiency of Nanoparticle-Silencing of Survivin, Bcl-2, and ABCG2 Genes
2.6. The Anti-CSC Effect of the Nanoparticles In Vitro
2.7. Hemocompatibility of the Nanoparticles
3. Discussion
4. Materials and Methods
4.1. Materials
4.2. Synthesis of BPEI–SH and DOX–SH
4.3. Synthesis of iRGD–PEG–HA
4.4. Preparation of SSBPEI–DOX@siRNAs and SSBPEI–DOX@siRNAs/iRGD–PEG–HA Nanoparticles
4.5. Characterization of Nanoparticles
4.6. Gel Retardation Assay
4.7. Reduction Responsiveness Test
4.8. Hemolysis Assay
4.9. Cell Culture
4.9.1. A2780/DDP Cell Culture
4.9.2. Spherical Culture of Stem Cell Microspheres
4.10. Characterization of Sphere-Forming Cells
4.11. Detection of Cell Uptake by Flow Cytometry
4.12. In Vivo Biodistribution
4.13. Real-Time PCR
4.14. Cytotoxicity
4.15. Annexin V-FITC/PI Double Staining
4.16. In Vitro Cell Migration and Invasion Assay
4.17. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hao, L.; Wang, J.-M.; Liu, B.-Q.; Yan, J.; Li, C.; Jiang, J.-Y.; Zhao, F.-Y.; Qiao, H.-Y.; Wang, H.-Q. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim. Biophys. Acta Mol. Cell Res. 2021, 1868, 118878. [Google Scholar] [CrossRef] [PubMed]
- Lytle, N.K.; Barber, A.G.; Reya, T. Stem cell fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer 2018, 18, 669–680. [Google Scholar] [CrossRef] [PubMed]
- Kimbung, S.; Loman, N.; Hedenfalk, I. Clinical and molecular complexity of breast cancer metastases. Semin. Cancer Biol. 2015, 35, 85–95. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van Vlerken, L.E.; Vyas, T.K.; Amiji, M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 2007, 24, 1405–1414. [Google Scholar] [CrossRef]
- Resnier, P.; Montier, T.; Mathieu, V.; Benoit, J.P.; Passirani, C. A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials 2013, 34, 6429–6443. [Google Scholar] [CrossRef]
- Davis, M.E.; Zuckerman, J.E.; Choi, C.H.; Seligson, D.; Tolcher, A.; Alabi, C.A.; Yen, Y.; Heidel, J.D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464, 1067–1070. [Google Scholar] [CrossRef] [Green Version]
- Zheng, M.; Liu, Y.; Wang, Y.; Zhang, D.; Zou, Y.; Ruan, W.; Yin, J.; Tao, W.; Park, J.B.; Shi, B. ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy. Adv. Mater. 2019, 31, e1903277. [Google Scholar] [CrossRef]
- Majumdar, R.; Rajasekaran, K.; Cary, J.W. RNA Interference (RNAi) as a Potential Tool for Control of Mycotoxin Contamination in Crop Plants: Concepts and Considerations. Front. Plant Sci. 2017, 8, 200. [Google Scholar] [CrossRef] [Green Version]
- Han, L.; Tang, C.; Yin, C. Enhanced antitumor efficacies of multifunctional nanocomplexes through knocking down the barriers for siRNA delivery. Biomaterials 2015, 44, 111–121. [Google Scholar] [CrossRef]
- Zins, K.; Sioud, M.; Aharinejad, S.; Lucas, T.; Abraham, D. Modulating the tumor microenvironment with RNA interference as a cancer treatment strategy. Methods Mol. Biol. 2015, 1218, 143–161. [Google Scholar] [CrossRef]
- Kim, W.J.; Kim, S.W. Efficient siRNA delivery with non-viral polymeric vehicles. Pharm. Res. 2009, 26, 657–666. [Google Scholar] [CrossRef]
- Zhang, T.; Xue, X.; He, D.; Hsieh, J.T. A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA. Cancer Lett. 2015, 365, 156–165. [Google Scholar] [CrossRef]
- Son, S.; Singha, K.; Kim, W.J. Bioreducible BPEI-SS-PEG-cNGR polymer as a tumor targeted nonviral gene carrier. Biomaterials 2010, 31, 6344–6354. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Cai, X.; Hu, J.; Shao, N.; Wang, F.; Zhang, Q.; Xiao, J.; Cheng, Y. Glutathione-triggered “off-on” release of anticancer drugs from dendrimer-encapsulated gold nanoparticles. J. Am. Chem. Soc. 2013, 135, 9805–9810. [Google Scholar] [CrossRef] [PubMed]
- Felice, B.; Prabhakaran, M.P.; Rodriguez, A.P.; Ramakrishna, S. Drug delivery vehicles on a nano-engineering perspective. Mater. Sci. Eng. C Mater. Biol. Appl. 2014, 41, 178–195. [Google Scholar] [CrossRef] [PubMed]
- Hiraga, T.; Ito, S.; Nakamura, H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 2013, 73, 4112–4122. [Google Scholar] [CrossRef] [Green Version]
- Hiscox, S.; Baruha, B.; Smith, C.; Bellerby, R.; Goddard, L.; Jordan, N.; Poghosyan, Z.; Nicholson, R.I.; Barrett-Lee, P.; Gee, J. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer 2012, 12, 458. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grover, R.; Drall, S.; Poonia, N.; Jain, G.K.; Aggarwal, G.; Lather, V.; Kesharwani, P.; Pandita, D.; Goyal, R.K. CD44 and CD133 aptamer directed nanocarriers for cancer stem cells targeting. Eur. Polym. J. 2023, 183, 111770. [Google Scholar] [CrossRef]
- Xu, H.X.; Niu, M.K.; Yuan, X.; Wu, K.M.; Liu, A.G. CD44 as a tumor biomarker and therapeutic target. Exp. Hematol. Oncol. 2020, 9, 36. [Google Scholar] [CrossRef] [PubMed]
- Liu, D.; Liu, T.; Li, R.; Sy, M.S. Mechanisms regulating the binding activity of CD44 to hyaluronic acid. Front. Biosci. 1998, 3, d631–d636. [Google Scholar] [CrossRef] [Green Version]
- Mattheolabakis, G.; Milane, L.; Singh, A.; Amiji, M.M. Hyaluronic acid targeting of CD44 for cancer therapy: From receptor biology to nanomedicine. J. Drug Target. 2015, 23, 605–618. [Google Scholar] [CrossRef] [PubMed]
- Cannito, S.; Bincoletto, V.; Turato, C.; Pontisso, P.; Scupoli, M.T.; Ailuno, G.; Andreana, I.; Stella, B.; Arpicco, S.; Bocca, C. Hyaluronated and PEGylated Liposomes as a Potential Drug-Delivery Strategy to Specifically Target Liver Cancer and Inflammatory Cells. Molecules 2022, 27, 1062. [Google Scholar] [CrossRef] [PubMed]
- Hu, Q.L.; Jiang, Q.Y.; Jin, X.; Shen, J.; Wang, K.; Li, Y.B.; Xu, F.J.; Tang, G.P.; Li, Z.H. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials 2013, 34, 2265–2276. [Google Scholar] [CrossRef]
- Sugahara, K.N.; Teesalu, T.; Karmali, P.P.; Kotamraju, V.R.; Agemy, L.; Greenwald, D.R.; Ruoslahti, E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328, 1031–1035. [Google Scholar] [CrossRef] [Green Version]
- Chaudhary, B.; Khaled, Y.S.; Ammori, B.J.; Elkord, E. Neuropilin 1: Function and therapeutic potential in cancer. Cancer Immunol. Immunother. 2014, 63, 81–99. [Google Scholar] [CrossRef] [PubMed]
- Jimenez-Hernandez, L.E.; Vazquez-Santilan, K.; Castro-Oropeza, R.; Martinez-Ruiz, G.; Munoz-Galindo, L.; Gonzalez-Tores, C.; Cortes-Gonzalez, C.C.; Victoria-Acosta, G.; Melendez-Zajgla, J.; Maldonado, V. NRP1-positive lung cancer cells possess tumor-initiating properties. Oncol. Rep. 2018, 39, 349–357. [Google Scholar] [CrossRef] [Green Version]
- Beck, B.; Driessens, G.; Goossens, S.; Youssef, K.K.; Kuchnio, A.; Caauwe, A.; Sotiropoulou, P.A.; Loges, S.; Lapouge, G.; Candi, A.; et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478, 399–402. [Google Scholar] [CrossRef]
- Liu, Y.X.; Zong, Y.H.; Yang, Z.X.; Luo, M.; Li, G.L.; Wang, Y.S.; Cao, Y.L.; Xiao, M.; Kong, T.J.; He, J.; et al. Dual-Targeted Controlled Delivery Based on Folic Acid Modified Pectin-Based Nanoparticles for Combination Therapy of Liver Cancer. Acs Sustain. Chem. Eng. 2019, 7, 3614–3623. [Google Scholar] [CrossRef]
- Vikas; Sahu, H.K.; Mehata, A.K.; Viswanadh, M.K.; Priya, V.; Muthu, M.S. Dual-receptor-targeted nanomedicines: Emerging trends and advances in lung cancer therapeutics. Nanomedicine 2022, 17, 1375–1395. [Google Scholar] [CrossRef] [PubMed]
- Li, R.; Peng, Y.; Pu, Y.C.; Zhao, Y.; Nie, R.F.; Guo, L.; Wu, Y. Fructose and biotin co-modified liposomes for dual-targeting breast cancer. J. Liposome Res. 2022, 32, 119–128. [Google Scholar] [CrossRef]
- Tian, Y.; Li, S.; Song, J.; Ji, T.; Zhu, M.; Anderson, G.J.; Wei, J.; Nie, G. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 35, 2383–2390. [Google Scholar] [CrossRef]
- Wang, T.; Gantier, M.P.; Xiang, D.; Bean, A.G.; Bruce, M.; Zhou, S.-F.; Khasraw, M.; Ward, A.; Wang, L.; Wei, M.Q.; et al. EpCAM aptamer-mediated survivin silencing sensitized cancer stem cells to Doxorubicin in a breast cancer model. Theranostics 2015, 5, 1456–1472. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ray, L. Synergistic anticancer activity by co-delivered nanosized dual therapeutic agents and siRNA in colon cancer. J. Drug Deliv. Sci. Technol. 2020, 55, 101351. [Google Scholar] [CrossRef]
- Ma, J.; Kala, S.; Yung, S.; Chan, T.M.; Cao, Y.; Jiang, Y.; Liu, X.; Giorgio, S.; Peng, L.; Wong, A.S.T. Blocking Stemness and Metastatic Properties of Ovarian Cancer Cells by Targeting p70(S6K) with Dendrimer Nanovector-Based siRNA Delivery. Mol. Ther. 2018, 26, 70–83. [Google Scholar] [CrossRef] [PubMed]
- Ahmadov, I.; Bandaliyeva, A.; Nasibova, A.; Hasanova, F.; Khalilov, R.I. The synthesis of the silver nanodrugs in the medicinal plant Baikal skullcap (scutellaria baicalensis georgi) and their antioxidant, antibacterial activity. Adv. Biol. Earth Sci. 2020, 5, 103–118. [Google Scholar]
- Hasanzadeh, A.; Khalilov, R.; Abasi, E.; Saghfi, S.; Nasibova, A.; Akbarzadeh, A.J.A.i.B.; Sciences, E. Development of doxorubicin-adsorbed magnetic nanoparticles modified with biocompatible copolymers for targeted drug delivery in lung cancer. Adv. Biol. Earth Sci. 2017, 2, 5–21. [Google Scholar]
- Guo, R.R.; Peng, H.B.; Tian, Y.; Shen, S.; Yang, W.L. Mitochondria-Targeting Magnetic Composite Nanoparticles for Enhanced Phototherapy of Cancer. Small 2016, 12, 4541–4552. [Google Scholar] [CrossRef]
- Cheng, C.; Zhang, Z.; Wang, S.; Chen, L.; Liu, Q. Reduction sensitive CC9-PEG-SSBPEI/miR-148b nanoparticles: Synthesis, characterization, targeting delivery and application for anti-metastasis. Colloids Surf. B Biointerfaces 2019, 183, 110412. [Google Scholar] [CrossRef]
- Chen, L.; Wang, S.; Liu, Q.; Zhang, Z.; Lin, S.; Zheng, Q.; Cheng, M.; Li, Y.; Cheng, C. Reduction sensitive nanocarriers mPEG-g-γ-PGA/SSBPEI@siRNA for effective targeted delivery of survivin siRNA against NSCLC. Colloids Surf. B Biointerfaces 2020, 193, 111105. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chen, L.; Luo, J.; Zhang, J.; Wang, S.; Sun, Y.; Liu, Q.; Cheng, C. Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome Ovarian Cancer Stem Cells. Int. J. Mol. Sci. 2023, 24, 11575. https://doi.org/10.3390/ijms241411575
Chen L, Luo J, Zhang J, Wang S, Sun Y, Liu Q, Cheng C. Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome Ovarian Cancer Stem Cells. International Journal of Molecular Sciences. 2023; 24(14):11575. https://doi.org/10.3390/ijms241411575
Chicago/Turabian StyleChen, Li, Jinlan Luo, Jingyuan Zhang, Siyuan Wang, Yang Sun, Qinying Liu, and Cui Cheng. 2023. "Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome Ovarian Cancer Stem Cells" International Journal of Molecular Sciences 24, no. 14: 11575. https://doi.org/10.3390/ijms241411575